update of manifest phase 2 study
Published 3 years ago • 6 plays • Length 2:21Download video MP4
Download video MP3
Similar videos
-
2:21
update of manifest phase 2 study
-
1:30
insights into the manifest-2 study
-
1:49
results from manifest phase ii study of pelabresib for anemia associated with myelofibrosis
-
3:44
phase ii study update of navtemadlin in patients with myelofibrosis r/r to ruxolitinib
-
2:03
an update on the phase ii/iii imerge trial of imetelstat in lr-mds
-
0:48
updates and correlative results from the manifest-2 trial
-
2:10
manifest update: pelabresib clinical and pathological investigations
-
3:56
an update on manifest: pelabresib monotherapy or as add-on to ruxolitinib in myelofibrosis
-
1:20
advancements in second-line immunotherapy for cholangiocarcinoma
-
1:43
phase ii pathway: adjuvant pembrolizumab in patients with hnsc cancer at high risk for recurrence
-
1:38
an update on the optic study: adjusting the dose of ponatinib for cp-cml
-
1:34
pelabresib in myelofibrosis: the manifest trials
-
3:33
manifest: pelabresib (cpi-0610) shows promise in myelofibrosis
-
1:08
dr. kremyanskaya on responses with cpi-0610 in patients with myelofibrosis
-
4:19
phase ii trial of first line futibatinib and pembrolizumab in platinum-ineligible muc
-
1:04
phase ii trial of nivolumab and relatlimab in mss crc
-
1:06
novel advances in cholangiocarcinoma
-
13:39
raajit rampal, md, phd & naveen pemmaraju, md: manifest-2 and transform-1 trials
-
2:08
pelabresib (cpi-0610): a novel bet inhibitor for mf